Biopharma | June 29, 2025
Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
Extended lab space for product development, customer demos, and training
Extended lab space for product development, customer demos, and training
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Star Health Insurance is modernising its claims ecosystem to be future-ready
The inspection concluded with zero Form 483 observations
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Changhua site meets international regulatory standards for global medical applications
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Subscribe To Our Newsletter & Stay Updated
